Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia

Pierre Laneuville, Michael Jeremy Barnett, Robert Belanger, Stephen Couban, Donna Lynn Forrest, Denis-Claude Roy, Jeffrey Howard Lipton



Chronic myelogenous leukemia (CML) is a disease characterized by the expression of bcr/abl, an oncogenic protein tyrosine kinase, and evolution over time from a relatively benign chronic phase (CP) to a rapidly fatal CML blast crisis (BC). Until recently, the standard of care included potentially curative therapy with allogeneic stem cell transplantation (ASCT), available only to a minority (about 10%) of patients, or medical therapy with interferon-alpha with or without cytarabine that helped to prolong the chronic phase of the disease in a minority of patients. The availability of imatinib mesylate, a selective inhibitor of bcr/ablK approved by Health Canada in 2001, has profoundly altered the clinical and laboratory management of CML. This change in practice has been reviewed by the Canadian Consensus Group on the Management of Chronic Myelogenous Leukemia (CCGM-CML) and resulted in a new set of recommendations for the optimal care of CML patients.

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)